Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/08/2019 11/11/2019 11/12/2019 11/13/2019 11/14/2019 Date
201.31(c) 201.9(c) 203.86(c) 207.1(c) 205(c) Last
1 220 080 825 165 939 805 1 101 055 995 539 Volume
+2.80% +0.29% +0.97% +1.59% -1.01% Change
More quotes
Financials (USD)
Sales 2019 3 756 M
EBIT 2019 1 599 M
Net income 2019 796 M
Finance 2019 3 397 M
Yield 2019 -
Sales 2020 4 770 M
EBIT 2020 2 297 M
Net income 2020 1 328 M
Finance 2020 4 774 M
Yield 2020 -
P/E ratio 2019 66,6x
P/E ratio 2020 40,9x
EV / Sales2019 13,1x
EV / Sales2020 10,1x
Capitalization 52 716 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.7%); - royalties and... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
11/13VERTEX PHARMACEUTICALS : Confirms Wales Offer Accepted for Access to All License..
BU
11/12VERTEX PHARMACEUTICALS :  Vertex Confirms Northern Ireland Offer Accepted for Cy..
BU
11/07VERTEX PHARMACEUTICALS : to Present at the Credit Suisse Healthcare Conference o..
BU
11/01VERTEX PHARMACEUTICALS : Phase 3 Results from Two Studies of TRIKAFTA Triple Com..
AQ
10/31VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
10/31VERTEX PHARMACEUTICALS : Phase 3 Results from Two Studies of TRIKAFTA (elexacaft..
BU
10/31VERTEX : Announces European Medicines Agency Marketing Authorization Application..
BU
10/30VERTEX : 3Q Earnings Snapshot
AQ
10/30VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
10/30VERTEX PHARMACEUTICALS : Reports Third-Quarter 2019 Financial Results
BU
10/25VERTEX PHARMACEUTICALS : Petitions Committee welcomes deal on cystic fibrosis dr..
AQ
10/24VERTEX PHARMACEUTICALS : Announces Agreement with NHS England for Access to All ..
BU
10/22VERTEX PHARMACEUTICALS : FDA Approves TRIKAFTA to Treat the Underlying Cause of ..
AQ
10/22VERTEX PHARMACEUTICALS : Spanish Government Approves National Reimbursement of O..
AQ
10/21VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2019 Financial Results on Oct..
BU
More news
News in other languages on VERTEX PHARMACEUTICALS
09/23VERTEX PHARMACEUTICALS : en baisse, mais un analyste positif
09/23VERTEX PHARMACEUTICALS : Jefferies reste à l'achat
08/30GROWTH VS. VALUE : qui gagne depuis 15 ans ?
2018WALL STREET STOCK EXCHANGE : Wall Street termine dans le rouge après la Fed lest..
2018VERTEX PHARMACEUTICALS : meldet Erstattungsvereinbarung in Australien für ORKAMB..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 225,58  $
Last Close Price 205,00  $
Spread / Highest target 39,0%
Spread / Average Target 10,0%
Spread / Lowest Target -8,78%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Charles F. Wagner Chief Financial Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS23.71%52 716
GILEAD SCIENCES2.01%80 729
REGENERON PHARMACEUTICALS-9.40%36 994
WUXI APPTEC CO., LTD.83.91%22 688
GENMAB39.63%14 293
BEIGENE, LTD.40.03%11 907